PhotonPharma, a biopharmaceutical company focused on developing innovative cancer treatments, has successfully secured $2.5 million in seed funding. This investment will fuel the advancement of Innocell, a promising therapy designed to target advanced ovarian cancer.
 
The funding round marks a significant milestone for PhotonPharma as the company prepares to initiate a Phase I clinical trial for Innocell. The trial is expected to enroll its first patient in the fourth quarter of 2024, providing valuable data on the safety and efficacy of the therapy.
 
“This funding is a significant milestone for PhotonPharma and marks a pivotal moment in our mission to advance breakthrough therapies for cancer therapies,” said Dr. Terry Opgenorth, Chairman of the Board of Directors of PhotonPharma. “We are excited to move forward with our clinical trials and are grateful for the support of our investors, whose confidence will help drive the development of our technology platform forward.”
 
PhotonPharma will be presenting its progress and development plans at the upcoming Rocky Mountain Life Sciences Investor and Partnering Conference. This event will offer an opportunity for investors and industry partners to learn more about the company’s innovative approach and the potential impact of Innocell on ovarian cancer treatment.